Effect of Telitacicept on Antibody Titers in Primary APS Patients
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles.